Immune checkpoint inhibitor (ICI) therapy has transformed cancer treatment, but up to 40% of patients develop immune-related adverse events such as colitis.
My ongoing research investigates whether pre-existing epigenetic states in HSPCs can predict susceptibility to ICI-associated colitis. By integrating longitudinal patient cohorts, single-cell multi-omics, and murine models, I aim to define how interferon-driven hematopoietic memory reprograms both immune and epithelial compartments.
A key goal is understanding how therapeutic interventions remodel these programs while preserving anti-tumor immunity.